Triterpenoid Therapeutics
- Biotech or pharma, therapeutic R&D
Triterpenoid Therapeutics ("TTX") is advancing a class of multi-pathway small molecules that simultaneously suppress inflammatory signaling and enhance cellular antioxidant defenses – targeting the NLRP3 Inflammasome and key regulators of the integrated stress response (ISR) which overlap and influence the progression of neurodegenerative diseases and therapy resistance in cancer. TTX’s compounds are unique in their capacity to inhibit NLRP3 activation while modulating essential components of the ISR as their primary mechanism of action. Preclinical data demonstrate that our lead compound, 2P-Im (TTX-01) effectively crosses the blood-brain barrier, with a safety profile that is validated by the regulatory approval of an “in-class” molecule (Omaveloxolone/ "Skyclarys") sharing our synthetic scaffold foundation. Founded upon decades of rigorous science, TTX’s expansive pipeline is transforming the treatment landscape for neurodegenerative diseases, neuro-oncology and beyond.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}